![Peter Olagunju](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Olagunju
Direttore operativo presso
TCR2 THERAPEUTICS INC.
Profilo
Peter Olagunju is currently the Chief Operating Officer at TCR2 Therapeutics, Inc. He previously worked as the Head-Quality at Dendreon Corp.
and ZymoGenetics, Inc. From 2015 to 2020, he served as the Vice President-Global Patient Operations at bluebird bio, Inc. and from 2020 to 2021, he was the Senior Vice President-Technical Operations at FerGene, Inc. Mr. Olagunju holds an MBA from the University of Washington and an undergraduate degree from the University of Illinois At Urbana–Champaign.
Posizioni attive di Peter Olagunju
| Società | Posizione | Inizio |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Direttore operativo | 31/12/2022 |
Precedenti posizioni note di Peter Olagunju
| Società | Posizione | Fine |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Corporate Officer/Principal | 01/07/2021 |
| GENETIX BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2020 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
| DENDREON CORPORATION | Corporate Officer/Principal | - |
Formazione di Peter Olagunju
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
26
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of Illinois At Urbana–Champaign
 University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
